Killing dormant leukaemia cells to stop relapse
Targeting refractory and dormant stem cells in childhood leukaemia
Improving our understanding of immunotherapy in high-risk neuroblastoma
Understanding and improving the mechanism of action of anti-GD2 monoclonal antibody therapy in neuroblastoma
‘Starving’ brain tumours to death
Exploring alterations in amino acid metabolism as novel therapeutic targets in paediatric glial tumours using advanced metabolomics methods
Understanding how some leukaemia cells survive treatment and cause a relapse
Understanding and therapeutically exploiting clonal evolution in chemo-resistant acute lymphoblastic leukaemia
A new way of treating poor prognosis Wilms’ tumour
Targeting gain of function p53 in poor prognosis Wilms' tumour via histone methyltransferase inhibition
Understanding the biology of relapsed ependymoma brain tumours to help improve treatments
Deciphering the New Molecular Landscape in Paediatric Recurrent Ependymoma: Implications for Molecular Targeted Therapy
Using digital technology to improve our understanding of rhabdomyosarcoma
Deep learning: An integrated approach to define clinical significance to components of the tumour microenvironment of rhabdomyosarcomas
"Getting it right first time" for children with renal tumours
Improving prediction of relapse, treatment delivery and outcomes for children with renal tumours in the UK
Investigating the genetic pathways that control leukaemia growth
RNA helicase DDX3X regulates JAK-STAT signalling in acute lymphoblastic leukaemia